Showing results (221-230 of 245) with videos related to
Sort By:
Pageof 25
European Journal of Cancer (Oxford, England : 1990)|September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real studyClaudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.Cancers|January 11, 2022
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular CarcinomaAmbreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, et al.Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.JHEP Reports : Innovation in Hepatology|January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinomaLorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.JAMA Oncology|July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.Hepatology (Baltimore, Md.)|December 7, 2024
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapyBernhard Scheiner, Beodeul Kang, Lorenz Balcar, et al.Pageof 25